BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Subsidiary Wins UK Government Contract for Satellite Communication Devices

NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd, has secured its first contract with a central UK government department to supply Iridium Push-To-Talk (PTT) satellite communication devices and recurring airtime services. The devices, designed for secure and reliable global communication, will support government staff engaged in policy development and coordination. Initial shipments are scheduled for the second quarter and will not be impacted by recent U.S. tariffs. 

To view the full press release, visit https://ibn.fm/DJmcP 

About NextPlat Corp 

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc. 

NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted…

4 hours ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy and targeted treatments for…

4 hours ago

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast 

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary…

6 hours ago

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company…

1 day ago

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Signs Deal with Worldwide Leader in Specialized Diagnostics 

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced a Research License and…

1 day ago

BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone

Gyre Therapeutics (NASDAQ: GYRE) has made strong progress through the first three quarters of FY2025,…

1 day ago